These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 7812924)

  • 21. Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.
    Baba M; Kageyama S; Yoshida T; Fujiwara R; Kim CJ; Takimoto K; Nagasawa M; Soga H; Nagatani Y; Nishikawa Z; Kawauchi A
    Int J Clin Oncol; 2018 Oct; 23(5):951-956. PubMed ID: 29761307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PG; Oettgen HF; Melamed MR
    Urology; 1985 Feb; 25(2):119-23. PubMed ID: 3881870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
    Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
    J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
    Okuno H; Shirahase T; Kihara Y; Arai Y
    Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder.
    Takashi M; Shimoji T; Murase T; Sakata T; Sobajima T; Suzuki Y
    Int Urol Nephrol; 1997; 29(5):557-63. PubMed ID: 9413763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
    Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
    J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intravesical bacillus Calmette-Guerin instillation therapy of recurrent superficial bladder carcinomas resistant to intravesical anti-cancer chemotherapy].
    Takeuchi S; Kihara K; Higashi Y; Fukui I; Oshima H
    Hinyokika Kiyo; 1989 Apr; 35(4):577-81. PubMed ID: 2735262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.
    Cookson MS; Sarosdy MF
    J Urol; 1992 Sep; 148(3):797-801. PubMed ID: 1512829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence.
    Irie A; Uchida T; Yamashita H; Matsumoto K; Satoh T; Koh H; Shimura S; Iwamura M; Baba S
    Int J Urol; 2003 Apr; 10(4):183-9. PubMed ID: 12657096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
    Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
    BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
    Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
    J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
    Steg A; Belas M; Leleu C; Boccon-Gibod L
    Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
    [No Abstract]   [Full Text] [Related]  

  • 37. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
    Shelley MD; Kynaston H; Court J; Wilt TJ; Coles B; Burgon K; Mason MD
    BJU Int; 2001 Aug; 88(3):209-16. PubMed ID: 11488731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.
    van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R;
    J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intravesical Bacillus Calmette-Guerin (BCG: Tokyo 172 strain) instillation for carcinoma in situ of the bladder: results with 6 successive instillations of 40 mg BCG].
    Mugiya S; Nagata M; Takayama T; Ozono S; Ito T; Maruyama S; Hadano S; Nagae H
    Hinyokika Kiyo; 2004 Jul; 50(7):469-73. PubMed ID: 15334890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.